Based on emerging evidence demonstrating increased GFAP concentrations in biofluids from individuals with neurodegenerative diseases [20,21,22,23], we evaluated whether plasma or CSF GFAP is elevated in SCA7 patients compared to the controls. This evidence concerns the gene GFAP and spinocerebellar ataxia 7.